Teduglutide
Reviewed
Short answer
An established medicine that can reduce support given through a vein in short bowel syndrome. It needs intensive product-specific monitoring. Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein.
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Read the study findingsAlso known as Gattex · ALX-0600 · GLP-2 analogue
Part of Gut peptide medicines
Legal status Is Teduglutide legal? See the status table
Study and product details
What it is
Teduglutide is a changed version of GLP-2, a body signal that affects intestinal absorption. Gattex is approved for people with short bowel syndrome who depend on parenteral support, such as fluids or nutrition given through a vein.
Type of peptide: Glucagon-like peptide-2 analogue. This describes what the substance is or how it works. It does not show that it is safe, effective, or approved.
What has been studied?
- Strong: Several reliable sources describe this clearly.
Randomized trials support reduction in parenteral-support requirements for short bowel syndrome.
Intestinal absorption, exposure, and product effects are characterized in the label and trials.
The label addresses neoplastic growth, obstruction, biliary and pancreatic disease, and fluid imbalance.
High for authentic Gattex used within its monitoring program.
Products with the same ingredient can differ.
The ingredient name does not tell you everything about a product. Check its other ingredients, its form, how it enters the body, and the use and people covered by the research or approval.
Gattex
2025 label- Ingredients and form
- Powder and diluent for injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Short bowel syndrome with parenteral-support dependence in the adult and pediatric populations defined in the label.
- Gattex
- Short bowel syndrome with dependence on parenteral support in labeled adults and children
What studies found
Randomized trials found that some participants needed less fluid or nutrition through a vein. The product label defines required screening and ongoing monitoring.
The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.
Which products do these findings apply to?
Gattex evidence applies to a specific monitored prescription product. Gattex is a labeled prescription product used with structured monitoring. Its evidence does not establish general gut healing or equivalence for compounded GLP-2 analogues.
Fact checks
3 statements checked. Read what the results mean.
“Teduglutide can reduce parenteral-support needs in short bowel syndrome.”
Controlled trials and the Gattex label support this outcome in dependent short-bowel-syndrome populations.
- What this answer is based on
- Health results from a study with randomly assigned groups
- Limits of this answer
- Adults and labeled pediatric populations with short bowel syndrome dependent on parenteral support.
Sources for this fact check (2)
“Teduglutide is a general gut-healing peptide.”
The approved indication and outcome are specific to short bowel syndrome with parenteral-support dependence.
- What this answer is based on
- Official record or product label
- Limits of this answer
- The current Gattex indication.
Sources for this fact check (1)
“Because teduglutide promotes intestinal growth, it is low risk.”
The same biological activity underlies important warnings, including potential acceleration of neoplastic growth.
- What this answer is based on
- Official record or product label
- Limits of this answer
- Approved Gattex use with required screening and monitoring.
Sources for this fact check (1)
Risks and safety limits
This monitored prescription therapy has serious risks, including possible acceleration of neoplastic growth. No dosing, reconstitution, or self-treatment guidance is provided.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed .Check the rules for athletes ↗Terms used in the studies
- analog
- a changed version made to act like another substance
- randomized
- assigned to study groups by chance
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- outcome
- what the study measured
- peptide
- a short chain of amino acids
- indication
- the approved or studied use and patient group
- amino acid
- a small building block that makes peptides and proteins
Read the sources
Show 3 sources
Review history
Initial brief based on the 2025 Gattex label, randomized trial, and orphan-drug record.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.
Report a factual error